Видео ютуба по тегу Biocon Group Fy24 Growth Outlook

Biocon's Kiran Mazumdar Shaw On Strong Q4, Biosimilar Business & FY24 Outlook | Halftime Report
Biocon's Kiran Mazumdar Shaw On Strong Q4, Biosimilar Business & FY24 Outlook | Halftime Report
Biocon Q4: Muted Growth In Generic Business | Review By Kiran Mazumdar Shaw | Business News
Biocon Q4: Muted Growth In Generic Business | Review By Kiran Mazumdar Shaw | Business News
Biocon Appoints Peter Bains As Group CEO To Drive 'Synergistic' Growth: What's The Road Ahead?
Biocon Appoints Peter Bains As Group CEO To Drive 'Synergistic' Growth: What's The Road Ahead?
What Is The Street Expecting From Biocon & Syngene This Q2?
What Is The Street Expecting From Biocon & Syngene This Q2?
CEO of India's Biocon discusses first-quarter results
CEO of India's Biocon discusses first-quarter results
Q1 Review: Biocon's Profit, Margins Fall, Misses Estimates | BQ Prime
Q1 Review: Biocon's Profit, Margins Fall, Misses Estimates | BQ Prime
Strong Biosimilar Growth Powers Biocon | Trading Hour | CNBC TV18
Strong Biosimilar Growth Powers Biocon | Trading Hour | CNBC TV18
Q4 Review | Biocon March Quarter Net Profit Soars | BQ Prime
Q4 Review | Biocon March Quarter Net Profit Soars | BQ Prime
eClerx's Nadadhur Srinivasan On Q4 Results & FY24 Growth Outlook | Bazaar Open Exchange | CNBC TV18
eClerx's Nadadhur Srinivasan On Q4 Results & FY24 Growth Outlook | Bazaar Open Exchange | CNBC TV18
Biocon Founder on Equality in India's Biopharmaceutical Sector
Biocon Founder on Equality in India's Biopharmaceutical Sector
Focusing On Specialty Pharma Currently: Biocon
Focusing On Specialty Pharma Currently: Biocon
FY18 Will Be Exciting; See Major Approvals Coming: Biocon
FY18 Will Be Exciting; See Major Approvals Coming: Biocon
Biocon Earnings Call for Q4FY23 and Full Year
Biocon Earnings Call for Q4FY23 and Full Year
R&D spending: Our pipeline is our 'lifeline,' says Indian biotech firm
R&D spending: Our pipeline is our 'lifeline,' says Indian biotech firm
Our acquisition of Viatris business has been 'spooking the Indian investor,' biotechnology firm says
Our acquisition of Viatris business has been 'spooking the Indian investor,' biotechnology firm says
In insulin bio-similars, our only competitors are original manufacturers: Kiran Mazumdar Shaw,Biocon
In insulin bio-similars, our only competitors are original manufacturers: Kiran Mazumdar Shaw,Biocon
Biocon Set For New Biosimilar Launch
Biocon Set For New Biosimilar Launch
Why Are Analysts Betting On Biocon Shares? Detailed Analysis On Know Your Company | NDTV Profit
Why Are Analysts Betting On Biocon Shares? Detailed Analysis On Know Your Company | NDTV Profit
Exclusive | Biocon Biologics Q4: Serum Will Double Investment To $300 Mn
Exclusive | Biocon Biologics Q4: Serum Will Double Investment To $300 Mn
Q4 Review | Ashok Leyland MD Shares FY24 Growth Projections | BQ Prime
Q4 Review | Ashok Leyland MD Shares FY24 Growth Projections | BQ Prime
Kiran Mazumdar - Shaw, Executive Chairperson, Biocon & Biocon Biologics speaking on Q3FY23 earnings
Kiran Mazumdar - Shaw, Executive Chairperson, Biocon & Biocon Biologics speaking on Q3FY23 earnings